CRANBURY, N.J., Feb. 19, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced that it has enrolled the first patient in a Phase 2 clinical trial of topical

SAN DIEGO, Feb. 19, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the fourth quarter and year-end 2019, after the market close on

SAN CARLOS, Calif., Feb. 19, 2020 /PRNewswire/ -- ZAP Surgical Systems, Inc. today announced an agreement with Bonifatius Hospital in Lingen, Germany to acquire ZAP-X® stereotactic radiosurgery (SRS) technology.

CARLSBAD, Calif., Feb. 19, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, February 26th at 11:30 a.m. Eastern Time to discuss its 2019 financial results and report on pipeline and business progress.

NEWARK, Calif., Feb. 19, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present a corporate overview at the upcoming the SVB Leerink 9th Annual Global Healthcare Conference in New York.Pres

WASHINGTON, Feb. 19, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announces the appointment of Stephen Ray Mitchell, M.D. to its Board of Directors."Ray is a highly respected leader in academic medicine and globally recognized expert in Pediatrics," said Mihael H. Polymeropoulos, M.D., President a

MONMOUTH JUNCTION, N.J. and NORTH POINT, Hong Kong, Feb. 19, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care i

OLDWICK, N.J., Feb. 19, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will present at two upcoming  conferences:

LAVAL, Quebec, Feb. 19, 2020 /PRNewswire/ -- Fourth-Quarter 2019 Financial Results Revenues of $2.224 Billion GAAP Cash Generated from Operations of $234 Million GAAP Net Loss of $1.516 Billio

IRVING, Texas, Feb. 19, 2020 /PRNewswire/ -- Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced that